Nkarta, Inc.

NASDAQ:NKTX

Biotechnology

Healthcare
$1.15 +3.41%

+$0.09 today

Market cap
$82.37M
Beta
0.90
P/E (TTM)
-2.0
EPS (TTM)
-$1.35
52W Low $1.63High $3.65

Volume 0.81M

Average 0.75M

NKTX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Nkarta, Inc.NASDAQ: NKTX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $2.34M rose 1.8% year over year, ahead of the -5.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 21.1% from the prior quarter. Over 3 fiscal years it compounded at +20.5% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1.8% holds above the trailing-twelve-month pace of -5.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.34M-21.1% QoQ
Last fiscal yearDec 2025
$4.61M+105.9% YoY
LTMMar 2026
$8.74M-5.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.8%——
1 year+105.9%——
3-year CAGR+20.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
4.61M USD
Year-over-year change
+105.9%
4-year CAGR
+27.3%

Depreciation & Amortization vs competitors

How NKTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -5.0% is the 5th highest of 8, against a peer median of -2.3%.
  • Over three fiscal years its annual growth of +20.5% compares with a peer median of +2.2%.
NKTX Competitors
Depreciation & Amortization for NKTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FATEFate Therapeutics, Inc.LTM Mar 2026$11.71M USD-33.0%-12.3%185.5%
ALECAlector, Inc.LTM Mar 2026$8.78M USD+4.6%—47.7%
NKTXNkarta, Inc.LTM Mar 2026$8.74M USD-5.0%+20.5%—
PEPGPepGen Inc.LTM Mar 2026$3.2M USD-5.6%+118.5%—
MOLNMolecular Partners AGLTM Mar 2026CHF 2.37M CHF+2.1%-3.5%—
VORVor Biopharma Inc.LTM Mar 2026$2.09M USD-38.1%+4.6%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$1.14M USD-2.3%+2.2%—
FBRXForte Biosciences, Inc.LTM Mar 2026$70K USD+62.8%——
Peer median (excluding NKTX) —-2.3%+2.2%116.6%

Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(86.08M)(113.84M)(117.5M)(108.79M)(104.08M)
Depreciation & Amortization1.76M2.64M5.87M2.24M4.61M
Deferred Income Tax3.24M0000
Stock-Based Compensation14.46M16.86M17.2M16.73M8.56M
Change in Working Capital(1.64M)33.74M10.93M(12.16M)(435K)
Accounts Receivables00000
Inventory00000
Accounts Payables2.79M2.76M4.22M(4.47M)2.46M
Other Working Capital(4.44M)30.98M6.7M(7.69M)(2.9M)
Other Non-Cash Items337K3.61M(2.65M)2.29M2.65M
Operating Cash Flow(67.93M)(57M)(86.16M)(99.7M)(88.7M)
Capital Expenditures(5.03M)(47.11M)(28.15M)(4.41M)(1.21M)
Acquisitions (Net)(37.56K)137.58K000
Purchases of Investments(227.28M)(385.89M)(260.23M)(406.38M)(238.57M)
Sales of Investments264.84M248.31M367.4M281.23M340.09M
Other Investing Activities37.56K(137.58K)000
Investing Cash Flow32.53M(184.69M)79.02M(129.56M)100.32M
Debt Repayment00000
Common Stock Issued1.2M217.17M691K225.07M141K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities01.84M01.01M0
Financing Cash Flow1.2M219.01M691K226.08M141K
Effect of Forex Changes00000
Net Change in Cash(34.19M)(22.68M)(6.45M)(3.17M)11.76M
Free Cash Flow(72.95M)(104.11M)(114.31M)(104.11M)(89.91M)

Nkarta, Inc.

NASDAQ:NKTX

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.